The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up

MLA

Bridges, K., et al. The Risks and Benefits of Long-Term Use of Hydroxyurea in Sickle Cell Anemia: A 17.5 Year Follow-Up. Jan. 2010. EBSCOhost, https://doi.org/10.17615/y997-wd39.

APA

Bridges, K., Telfer, M., Ataga, K., Orringer, E., Hoehner, C., Hernandez, S., Valdez, S., Temple, D., Shurin, S., Johnson-Telfair, A., Hagar, W., Vichinsky, E., Smith, W., Steinberg, M. H., Kleman, K., Rosse, W., Waller, L., Barber, Y., Chow, J., … Ryans, P. (2010). The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. https://doi.org/10.17615/y997-wd39

Chicago

Bridges, K., M. Telfer, Kenneth Ataga, E. Orringer, C. Hoehner, S. Hernandez, S. Valdez, et al. 2010. “The Risks and Benefits of Long-Term Use of Hydroxyurea in Sickle Cell Anemia: A 17.5 Year Follow-Up,” January. doi:10.17615/y997-wd39.